Changes in the commercial brand of tacrolimus lead to subtherapeutic trough levels and acute rejection in renal transplant recipients.
Arreola Guerra Jose ManuelJosefina AlberúAlfredo Chew-WongDulce Maria MaciasJesus Hernández-RosalesLeslie Zuñiga-MacíasRodolfo Delgadillo-CastañedaGuadalupe Ricalde-RíosFabian Haro-AlcaldeJ Rafael Villafán-BernalCarmen L Ramos-MedellínRafael Reyes-AcevedoPublished in: Clinical transplantation (2019)
In Mexico, changes in TAC brand are associated with an elevated frequency of SubT levels. Brand changes and SubT levels are independently associated with acute rejection. The supply policies on TAC brands in Mexico require revision to avoid changing brands as much as possible.